Form 4: Foghorn Therapeutics: Insider Stock Transfers Detailed

Adrian Gottschalk, CEO and Director of Foghorn Therapeutics, reports significant transfers of company common stock between trusts.

Summary

• Adrian Gottschalk, Chief Executive Officer and Director of Foghorn Therapeutics Inc. (FHTX), has reported transactions involving the transfer of company common stock.
• On April 9, 2026, the Adrian H. Gottschalk 2023 Grantor Retained Annuity Trust (2023 GRAT), where Mr. Gottschalk is trustee and sole current beneficiary, distributed 47,497 shares of common stock to the Adrian H. Gottschalk Living Trust.
• The Living Trust, also managed by Mr. Gottschalk as trustee, subsequently held these shares.
• On April 10, 2026, the Adrian H. Gottschalk 2025 Grantor Retained Annuity Trust (2025 GRAT), with Mr. Gottschalk as trustee and sole current beneficiary, distributed 59,208 shares of common stock to the Living Trust.
• Following these transactions, Mr. Gottschalk's beneficial ownership through various trusts is detailed.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine internal trust transactions rather than new capital raises, sales, or significant acquisitions.

Positives

• The reporting person, Adrian Gottschalk, continues to hold significant beneficial ownership of Foghorn Therapeutics' common stock through various trusts.
• The transactions represent internal trust distributions, indicating continued management and oversight of company shares by leadership.

Negatives

• The filing details transfers of stock, not acquisitions or sales in the open market, so there's no direct financial gain or loss reported for the reporting person from these specific transactions.

Risks

• While not explicitly stated as a risk in this filing, significant internal stock transfers could be scrutinized by investors if they are perceived as a precursor to future sales or if they alter the reporting person's direct control or beneficial ownership in a material way.

Future Outlook

This filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. These reports are crucial for investors to understand the holdings and activities of company executives and directors, providing transparency into potential shifts in insider confidence or strategic financial planning.

Comparison to Industry Standards

• Form 4 filings are a regulatory requirement under Section 16 of the Securities Exchange Act of 1934 for all U.S. public companies, including Foghorn Therapeutics.
• The reporting of stock transfers between trusts by an executive like Adrian Gottschalk is a common occurrence and is subject to the same disclosure rules as any other insider transaction.

Related Party Transactions

• The transactions involve the transfer of common stock between trusts where Adrian Gottschalk is the trustee and/or sole current beneficiary, representing related party transactions.

Stakeholder Impact

• Shareholders: Transparency regarding insider holdings is maintained, allowing for informed investment decisions.
• Management: Demonstrates continued oversight and management of company stock through personal trusts.

Next Steps

• Continued monitoring of future Form 4 filings by Adrian Gottschalk and other insiders for any changes in beneficial ownership or potential sales.

Key Dates

Keywords

Foghorn Therapeutics, FHTX, Form 4, Insider Trading, Stock Transfer, Beneficial Ownership, Adrian Gottschalk, CEO, Director, Grantor Retained Annuity Trust, Living Trust